Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Esketamine and ketamine
17 evidence topics · 12 sources
CANMAT guideline: second-line adjunctive ketamine and intranasal esketamine
“which is approved by several regulatory agencies as an add-on treatment to an SSRI/SNRI or other antidepressant, for patients failing at least 2 adequate antidepressant trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is also growing evidence for relapse-prevention efficacy for both medications, with maintenance doses administered every 1 to 4 weeks” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, side effect potential and feasibility issues (i.e., the required monitoring of blood pressure and dissociative side effects) have downgraded adjunctive ketamine and intranasal esketamine to second-line recommendation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
VA/DoD guideline: ketamine or esketamine after several pharmacologic trials
NICE guideline: esketamine nasal spray not recommended
ICER assessment: esketamine and intravenous ketamine as comparators for psilocybin
Esketamine FDA-approved indications, including monotherapy
Esketamine dosing in treatment-resistant depression
Esketamine REMS and post-dose monitoring
Esketamine adverse reactions, contraindications, and blood pressure monitoring
Esketamine monotherapy study: change in MADRS total score at Day 28
TRANSFORM-2: esketamine plus a new oral antidepressant at Day 28
“The study enrolled adults with moderate to severe nonpsychotic depression and a history of nonresponse to at least two antidepressants in the current episode, with one antidepressant assessed prospectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of 435 patients screened, 227 underwent randomization and 197 completed the 28-day double-blind treatment phase.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Change in MADRS score with esketamine plus antidepressant was significantly greater than with antidepressant plus placebo at day 28 (difference of least square means=-4.0, SE=1.69, 95% CI=-7.31, -0.64)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“7% and 0.9% of patients in the respective treatment groups discontinued study drug because of an adverse event.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
TRANSFORM-3: esketamine in adults aged 65 years and older
“For the primary endpoint, the median-unbiased estimate of the treatment difference (95% CI) was -3.6 (-7.20, 0.07); weighted combination test using MMRM analyses z = 1.89, two-sided p = 0.059.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Esketamine/antidepressant did not achieve statistical significance for the primary endpoint.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
SUSTAIN-1: relapse prevention with continued esketamine
“Among the 297 adults (mean age [SD], 46.3 [11.13] years; 197 [66.3%] female) who entered the randomized maintenance phase, 176 achieved stable remission; 24 (26.7%) in the esketamine and antidepressant group and 39 (45.3%) in the antidepressant and placebo group experienced relapse (log-rank P = .003, number needed to treat [NNT], 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Esketamine and antidepressant treatment decreased the risk of relapse by 51% (hazard ratio [HR], 0.49; 95% CI, 0.29-0.84) among patients who achieved stable remission and 70% (HR, 0.30; 95% CI, 0.16-0.55) among those who achieved stable response compared with antidepressant and placebo treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SUSTAIN-3: long-term safety and maintenance of response
“At the interim data cutoff (01 December 2020), 1148 participants were enrolled, 458 at induction and 690 at optimization/maintenance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Common treatment-emergent adverse events (≥20%) were headache, dizziness, nausea, dissociation, somnolence, and nasopharyngitis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“with 35.6% and 46.1% of participants in remission (MADRS total score ≤12) at induction and optimization/maintenance endpoints, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Serious adverse events were reported for 171 (14.9%) of the 1148 participants during SUSTAIN-3, over 2769 cumulative patient-years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ESCAPE-TRD: esketamine compared with extended-release quetiapine augmentation
“Overall, 336 patients were assigned to the esketamine group and 340 to the quetiapine group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“More patients in the esketamine group than in the quetiapine group had remission at week 8 (91 of 336 patients [27.1%] vs. 60 of 340 patients [17.6%]; P = 0.003) and had no relapse through week 32 after remission at week 8 (73 of 336 patients [21.7%] vs. 48 of 340 patients [14.1%]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In an open-label, single-blind (with raters unaware of group assignments), multicenter, phase 3b, randomized, active-controlled trial” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
ELEKT-D: intravenous ketamine compared with electroconvulsive therapy
“During an initial 3-week treatment phase, patients received either ECT three times per week or ketamine (0.5 mg per kilogram of body weight over 40 minutes) twice per week.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 403 patients underwent randomization at five clinical sites; 200 patients were assigned to the ketamine group and 203 to the ECT group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 55.4% of the patients in the ketamine group and 41.2% of those in the ECT group had a response (difference, 14.2 percentage points; 95% confidence interval, 3.9 to 24.2; P<0.001 for the noninferiority of ketamine to ECT).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“ECT was associated with musculoskeletal adverse effects, whereas ketamine was associated with dissociation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ketamine and esketamine: Cochrane meta-analysis
“The evidence suggests that ketamine may result in an increase in response and remission compared with placebo at 24 hours odds ratio (OR) 3.94, 95% confidence interval (CI) 1.54 to 10.10; n = 185, studies = 7, very low-certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Esketamine treatment likely results in a large increase in participants achieving remission at 24 hours compared with placebo (OR 2.74, 95% CI 1.71 to 4.40; n = 894, studies = 5, moderate-certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The effects of ketamine lasted no more than one week after treatment and clearly disappeared after two weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Esketamine caused a lot more side effects than placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote